optically inactive 1-hydroxy-1-methyl-2-(buten-(3)-yl)-cyclohexane | 859818-90-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: optically inactive 1-hydroxy-1-methyl-2-(buten-(3)-yl)-cyclohexane
• 英文别名: Opt.-inakt. 1-Hydroxy-1-methyl-2-(buten-(3)-yl)-cyclohexan；2-(But-3-en-1-yl)-1-methylcyclohexan-1-ol；2-but-3-enyl-1-methylcyclohexan-1-ol
• CAS: 859818-90-9
• 化学式: C₁₁H₂₀O
• 分子量: 168.279
• InChiKey: ZTEAZGZDEAYCEP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.89
• 重原子数：
  12.0
• 可旋转键数：
  3.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  20.23
• 氢给体数：
  1.0
• 氢受体数：
  1.0

反应信息

• 作为反应物：
  描述：

  optically inactive 1-hydroxy-1-methyl-2-(buten-(3)-yl)-cyclohexane 在 磷酸 作用下， 生成 cis-9-methyl-2-octalin
  参考文献：
  名称：

  112.熔融碳环。第七部分 由不饱和叔醇制备环状烃。顺式-9-甲基-八氢萘和-十氢萘的合成以及角甲基的存在的证明

  摘要：

  DOI：

  10.1039/jr9360000470
• 作为产物：
  描述：

  甲基碘化镁 、 alkaline earth salt of/the/ methylsulfuric acid 在 乙醚 作用下， 生成 optically inactive 1-hydroxy-1-methyl-2-(buten-(3)-yl)-cyclohexane
  参考文献：
  名称：

  112.熔融碳环。第七部分 由不饱和叔醇制备环状烃。顺式-9-甲基-八氢萘和-十氢萘的合成以及角甲基的存在的证明

  摘要：

  DOI：

  10.1039/jr9360000470

文献信息

• 134. Fused carbon rings. Part XVIII. Further investigations of model substances of the sexual hormone type
  作者：V. C. E. Burnop、R. P. Linstead

  DOI：10.1039/jr9400000720

  日期：——
• Budesonide in collagenous colitis: A double-blind placebo-controlled trial with histologic follow-up
  作者：Filip Baert、Alain Schmit、Geert D'Haens、Franceska Dedeurwaerdere、Edouard Louis、Marc Cabooter、Martine De Vos、Fernand Fontaine、Serge Naegels、Piet Schurmans、Hedwig Stals、Karel Geboes、Paul Rutgeerts

  DOI：10.1053/gast.2002.30295

  日期：2002.1

  Background & Aims: Collagenous colitis (CC) is a well-described entity causing chronic diarrhea and characteristic histologic findings. Several treatment options have been suggested, but no controlled data are available. We conducted a placebo-controlled trial to show the clinical and histologic effects of budesonide in CC. Methods: Twenty-eight patients were randomly assigned to receive placebo (n = 14) or budesonide 9 mg daily (n = :14) for 8 weeks. Patients were evaluated clinically, and blinded biopsy specimens were analyzed from fixed locations at weeks 0 and 8. Clinical response was defined as a decrease of at least 50% in the disease activity score (number of bowel movements in the last 7 days). At week 8, nonresponders received open-label budesonide for the next 8-week period; responders discontinued treatment and were followed up. Results: Three patients discontinued the study prematurely. Intention-to-treat analysis showed clinical response in 8 of 14 patients in the budesonide group compared with 3 of 14 responders for placebo (P = 0.05) after 8 weeks of blinded therapy, together with improved stool consistency. Histologically, there was no change in the mean thickness of the Collagen band but a significant decrease of the lamina propria infiltrate in the budesonide group (P < 0.001). Conclusions: Budesonide is efficacious in inducing short-term clinical response in CC with significant reduction of the histologic infiltrate in the lamina propria.